Jacob Gottlieb and Stuart Weisbrod are currently going to work from one office. This will be taking place after the two have been working separately for almost two decades. Gottlieb and Weisbrod are geniuses when it comes to healthcare investment. They have known each other since they started working together at Merlin Biomed Group. The two are looking forward to collaborating in the future, but at the moment they will be sharing an office at Altium Capital
Merlin was established in 1998 with Weisbrod as a co-founder. Merlin is an investment firm that concentrated on healthcare industry with portfolios in pharmaceuticals, healthcare services, medical device as well as biotechnology. Weisbrod has been very successful in the healthcare investments. He had positions with Prudent-Bache, Merrill Lynch, Oracle Partners, and Harpel Partners. Stuart Weisbrod went to Colgate University where he attained his bachelor’s degree in Chemistry in 1975. He later went on to join Columbia University to achieve his MBA in Finance in 1986. He earned his Biochemistry Ph.D. from Princeton University in 1980.
The professional background of Stuart Weisbrod helped with the required experience as well as the network to create a winning team. This team involved Jacob Gottlieb. Gottlieb worked as a portfolio manager for Weisbrod in 2000. Gottlieb helped Merlin to gain returns more than 100% in 1999 and 2000. With other portfolio managers, Gottlieb became successful in creating massive profits, and this made him land famous clients including endowments, pension funds, family offices as well as high net worth people. However, in 2007, Merlin closed its doors and refunded its investors.
Since closing Merlin, Weisbrod established another investment company called Iguana Healthcare Partners. Stuart used the same strategy as Merlin to open Iguana. The firm heavily focuses on public institutions in the healthcare sector. These organizations include medical service, diagnostic, pharmaceuticals, healthcare services, health information technology, and biotechnology companies.
After leaving Merlin, Gottlieb began Visium, an asset management organization after many successful years in the financial field. Gottlieb started Visium with $300 million, and the company grew so fast to $2.5 billion in 2008. Visium was able to endure the financial crisis that took place in 2008. Like Merlin, Visium closed its doors in 2016. This was after some of its executives were blamed for insider trading as well as mismarking. Currently, Gottlieb is working on moving with his next venture as he clears up with his Visium organization. With the coming together of the two financial entrepreneurs, the financial industry is set to see significant changes.
Find out more about Jacob Gottlieb Altium: https://www.linkedin.com/in/jacob-gottlieb/